Beijing Konruns Pharmaceutical (603590.SH): KC1036 will be presented in poster form at the 2026 ASCO meeting for the treatment of advanced thymoma.
Kang Chen Pharmaceutical (603590.SH) announced that their independently developed KC1036 tablets (referred to as "KC1036") will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in the form of a poster, showcasing the Phase II clinical research data of KC1036 in treating advanced thymic tumors that have progressed after previous platinum-based chemotherapy.
Beijing Konruns Pharmaceutical (603590.SH) announced that their independently developed KC1036 tablet (referred to as "KC1036") will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in the form of a poster, showcasing the phase II clinical research data of KC1036 in the treatment of advanced thymic tumors progressing after platinum-based chemotherapy.
KC1036 is a class 1 innovative drug independently developed by the company, and the company holds global intellectual property rights to this product. KC1036 achieves anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. Currently, clinical research is underway for KC1036 in multiple indications including gastrointestinal tumors, thymic tumors, and Ewing's sarcoma in children.
Related Articles
YONGDA AUTO (03669) spent about HK$288,900 to buy back 350,000 shares on May 28th.
According to the share subscription agreement, CHINA BAOLI TEC (00164) issued 19.77 million subscription shares.
CHYY GP(08128) suggests implementing equity restructuring.
YONGDA AUTO (03669) spent about HK$288,900 to buy back 350,000 shares on May 28th.
According to the share subscription agreement, CHINA BAOLI TEC (00164) issued 19.77 million subscription shares.
CHYY GP(08128) suggests implementing equity restructuring.
